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We investigated variations in sensitivity of an immunochemical (I-FOBT) and a guaiac (G-FOBT) faecal occult blood test according to
type and location of lesions in an average-risk 50- to 74-year-old population. Screening for colorectal cancer by both non-rehydrated
Haemoccult II G-FOBT and Magstream I-FOBT was proposed to a sample of 20322 subjects. Of the 1615 subjects with at least one
positive test, colonoscopy results were available for 1277. A total of 43 invasive cancers and 270 high-risk adenomas were detected.
The gain in sensitivity associated with the I-FOBT was calculated using the ratio of sensitivities (RSN) according to type and location of
lesions, and amount of bleeding. The gain in sensitivity by using I-FOBT increased from invasive cancers (RSN¼1.48 (1.16–4.59)) to
high-risk adenomas (RSN¼3.32 (2.70–4.07)), and was inversely related to the amount of bleeding. Among cancers, the gain in
sensitivity was confined to rectal cancer (RSN¼2.09 (1.36–3.20)) and concerned good prognosis cancers, because they involve less
bleeding. Among high-risk adenomas, the gain in sensitivity was similar whatever the location. This study suggests that the gain in
sensitivity by using an I-FOBT instead of a G-FOBT greatly depends on the location of lesions and the amount of bleeding.
Concerning cancer, the gain seems to be confined to rectal cancer.
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It is now established that screening by measuring faecal occult
bleeding in average-risk populations can detect asymptomatic
colorectal cancers and precancerous lesions (high-risk adenomas).
A number of recently reviewed randomised trials have established
the efficacy of average-risk population screening using the
Haemoccult II guaiac faecal occult blood test (G-FOBT) to reduce
specific mortality related to colorectal cancer (Hewitson et al,
2008). However, the sensitivity of this test for the detection of
invasive cancer and adenomas limits the expected gain in terms of
mortality. Over the past 20 years, an alternative type of FOBT has
been developed based on the immunological detection of human
haemoglobin (Hb), and offering greater sensitivity for the
detection of invasive cancers and pre-neoplastic lesions (Morikawa
et al, 2005; Castiglione et al, 2007; Guittet et al, 2007; Levi et al,
2007). With these tests, the gain in sensitivity appears to be higher
for adenomas than for invasive cancers (Guittet et al, 2007).
Several authors have concluded that bleeding from high-risk
adenomas, measured by an immunochemical FOBT (I-FOBT), is
lower than bleeding from invasive cancers (Ciatto et al, 2007; Levi
et al, 2007). The influence of the location of the colonic lesion (in
particular adenomas) on the amount of measured bleeding has
been inconsistently observed (Ciatto et al, 2007; Levi et al, 2007).
Because lesion detection is based on bleeding, the amount of
bleeding is consequently likely to determine the detectability of the
lesion. Our aim was thus to compare the sensitivity of the
Magstream I-FOBT and the Haemoccult II G-FOBT according to
the type and the location of lesions in an average-risk 50- to
74-year-old population.
METHODS
Study design
As from June 2004, a screening programme has been implemented
using a conventional G-FOBT, the Haemoccult II, for individuals
aged 50–74 years in the geographic area of Calvados (Normandy,
France). The first 30000 attendants to screening were offered the
possibility to join a study comparing an I-FOBT (Immudia/RPHA)
and the conventional G-FOBT. This analysis focuses on the 20322
subjects having performed both tests from 1 June 2004 to 31
December 2005.
The design of the study has been detailed in a previous
publication (Guittet et al, 2007). Participants were asked to obtain,
at home, two faecal samples on two different days for the I-FOBT
and two faecal samples each from three consecutive stools for the
conventional G-FOBT. The use of the same stools for I-FOBT and
G-FOBT was not mandatory. No specific dietary restriction was
stipulated. Samples of both tests were sent to the central analysis
centre (Institut inter-Re ´gional pour la Sante ´, Tours, France) where
all tests were processed independently according to manufacturers’
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srecommendations, readers of the G-FOBT being blinded to the
I-FOBT result. Guaiac faecal occult blood tests with at least one
positive oval out of six were considered positive. The I-FOBT
was processed using a Magstream 1000 automated device. The
I-FOBT was considered positive when at least one of the two
samples contained at least 20ngml
 1 of Hb in the buffer, which
corresponds to 0.1–0.2mg Hb per gram stool. The subject and
practitioner were informed of the overall screening procedure
result, but were blinded to each individual test result. In the case of
a positive result (i.e. at least one of the FOBT result was positive),
the subject was invited to undergo a colonoscopy. The colono-
scopy was performed blinded to the I-FOBT and G-FOBT results.
The study was approved by the local ethics committee (Comite ´
Consultatif de Protection des Personnes dans la Recherche
Biome ´dicale) and all participants gave written informed consent.
Subjects were excluded from this analysis if the endoscopic
examination was incomplete (caecum not visualised). However, if
the colonoscopy was incomplete because of obstructing tumours
or if the incomplete colonoscopy had been completed by another
colonic examination (double-contrast barium enema or virtual
colonoscopy) that failed to reveal any polypoid lesion, the results
were included in the analysis. Hyperplastic polyps were not
included as neoplasia. Advanced colonic neoplasia was defined
as high-risk adenoma (adenomas measuring 10mm or more,
adenomas with high-grade dysplasia) or invasive cancer. Intra-
mucosal carcinoma and carcinoma in situ were classified as
adenoma with high-grade dysplasia. The criterion for diagnosing
cancer was an invasion of malignant cells beyond the muscularis
mucosa. If a subject had more than one polyp, the most advanced
pathological lesion or the largest lesion was included in the
analysis.
Study population – Statistical analysis
The population of eligible subjects comprised of all subjects with
both I-FOBT and G-FOBT analysable results who had also given
informed consent, from 1 June 2004 to 31 December 2005
(n¼20322). Among the 1615 subjects with a positive screening
test (positive G-FOBT and/or I-FOBT), 1387 (85.9%) performed the
indicated colonoscopy. The frequency of subjects undergoing
endoscopic examination did not differ depending on which FOBT
was positive (G-FOBT and I-FOBT positive, 82.6%; G-FOBT
positive only, 84.9%; I-FOBT positive only, 84.6%, P¼0.77).
Fifty-nine subjects with incomplete colonoscopy, and 27 for whom
information on the polypoid lesion was insufficient, were excluded
from the analysis. Consequently, 1277 subjects with at least one
positive test and having completed a satisfactory colonoscopy were
included in the analysis.
Because the confirmatory procedure (colonoscopy) was re-
stricted to subjects classified as positive by at least one of the tests,
the sensitivity and specificity of each test could not be directly
estimated. We therefore compared the sensitivity of each test to
detect high-risk adenomas or invasive cancers according to the
location of lesions using the ratio of sensitivities (RSN) (Schatzkin
et al, 1987; Cheng and Macaluso, 1997). Briefly, if we denote by m0
1
the number of true positive subjects for the I-FOBT and by n0
1 the
number of true positive subjects for the G-FOBT, RSN is calculated
as: RSNI FOBT/G FOBT¼m0
1/n0
1. We compared the relative gain in
sensitivity between lesions using a marginal regression approach
involving a log-link function and an independence working
covariance matrix by applying a generalised estimating equation
(Sullivan Pepe and Alonzo, 2001).
The maximal faecal occult bleeding measured by the Magstream
I-FOBT was compared according to location and type of lesions
among subjects with a maximum of one lesion.
Statistical analysis was performed using SAS software version
9.1 (SAS Institute).
RESULTS
Table 1 shows the colonoscopy findings for the 1277 participants
with at least one positive test and a satisfactory colonoscopy result.
Among them, 390 (30.5%) had a positive G-FOBT and 1028
(80.5%) had a positive I-FOBT. Invasive cancers were detected for
43 subjects and at least one high-risk adenoma (size X10mm or
high-grade dysplasia) was observed for 270 subjects without
cancer. Table 2 illustrates that most of the high-risk adenomas
were detected in the distal colon, whereas half of the invasive
cancers were located in the rectum. Fourteen (34.1%) of the
invasive cancers were detected at early stage of extension (stage
T1-T2 N0 M0 of the Tumour Node Metastasis classification).
Comparison of performance between G-FOBT and I-FOBT
Table 3 shows the results of colonoscopy according to the results of
both tests: guaiac and immunochemical tests positive (G
þI
þ),
guaiac test positive and immunochemical test negative (G
þI
 ),
Table 1 Characteristics of subjects with positive tests and colonoscopy findings according to the kind of test (I-FOBT vs G-FOBT
a)
Positive G-FOBT
b (n¼390) Positive I-FOBT
c (n¼1028) Overall (n¼1277)
Sex (%)
Male 176 (45.1) 553 (53.8) 649 (50.8)
Female 214 (54.9) 475 (46.2) 628 (49.2)
Age
Mean (s.d.) (years) 63.65 (6.57) 63.53 (6.90) 63.44 (6.82)
50–54 (n (%)) 41 (10.5) 133 (12.9) 162 (12.7)
55–59 (n (%)) 82 (21.0) 228 (22.2) 286 (22.4)
60–64 (n (%)) 85 (21.8) 202 (19.7) 257 (20.1)
65–69 (n (%)) 98 (25.1) 237 (23.1) 299 (23.4)
70–74 (n (%)) 84 (21.5) 228 (22.2) 273 (21.4)
Colonoscopy findings
Invasive cancer 27 (6.9) 41 (4.0) 43 (3.4)
High-risk adenoma
c 76 (19.5) 250 (24.3) 270 (21.1)
Small adenoma 57 (14.6) 211 (20.5) 251 (19.7)
Normal colon 230 (59.0) 526 (51.2) 713 (55.8)
aG-FOBT¼guaiac faecal occult blood test; I-FOBT¼immunochemical faecal occult blood test.
bIncluding 141 subjects who were positive for G-FOBT and I-FOBT.
cAdenoma
X10mm or high-grade dysplasia.
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sguaiac test negative and immunochemical test positive (G
 I
þ).
The positive predictive value (PPV) was lower for I-FOBT than for
G-FOBT with regard to invasive cancers (4.0 vs 6.9%; P¼0.03),
and higher with regard to high-risk adenomas (24.3 vs 19.5%).
Using the RSN, Table 3 compares the sensitivity of I-FOBT and
G-FOBT for the detection of invasive cancers and high-risk
adenomas according to the location of the lesion. The sensitivity of
I-FOBT was higher than that of G-FOBT for invasive cancer
(RSN¼1.48 (1.16–1.89)) and high-risk adenomas (RSN¼3.32
(2.70–4.07)). The increase in sensitivity for the detection of
high-risk adenomas was significantly greater than that of invasive
cancers (Po10
 3). Concerning cancer, the increase in sensitivity
of I-FOBT compared to G-FOBT was far higher for rectal cancers
than for other localisations. In fact, the gain in sensitivity for
cancer was restricted to invasive cancers located in the rectum
(RSNrectal cancer4RSNcolonic cancer, P¼0.013), the gain for other
localisations being non-significant. Table 4 illustrates that the
majority of the invasive cancers missed by the G-FOBT and
detected by the I-FOBT were good prognosis cancers (T1-T2 N0
M0) located in the rectum. Concerning high-risk adenoma, the
gain in sensitivity did not depend on the location.
Physiological rationale
Amount of bleeding according to the type and location of the
lesion Figure 1 shows the percentile of distribution of the
maximal amount of bleeding measured for each I-FOBT-positive
subjects by the automatic I-FOBT reader according to the type and
location of the lesion. Subjects with more than one lesion were
excluded from this analysis. Independent of the location, the
Table 2 Characteristics of the subjects, location and extension of lesion according to colonoscopy findings
Invasive cancer (n¼43) High-risk adenoma (n¼270) Other (n¼964)
Sex (%)
Male 23 (53.5) 170 (63.0) 456 (47.3)
Female 20 (46.5) 100 (37.0) 508 (52.7)
Age
Mean (s.d.) (years) 65.52 (6.18) 64.34 (6.68) 63.15 (6.88)
50–54 (n (%)) 3 (7.0) 23 (8.5) 136 (14.1)
55–59 (n (%)) 6 (14.0) 58 (21.5) 222 (23.0)
60–64 (n (%)) 10 (23.3) 53 (19.6) 194 (20.1)
65–69 (n (%)) 10 (23.3) 74 (27.4) 215 (22.3)
70–74 (n (%)) 14 (33.6) 62 (23.0) 197 (20.4)
Location
a
Rectum
b 23 (52.3) 55 (19.4) NA
Distal colon
c 15 (34.1) 177 (62.5) NA
Proximal colon
d 6 (13.6) 51 (18.0) NA
Missing 0 5 NA
Stage
a,e
T1-T2 N0 M0 14 (34.1) NA NA
T3-T4 N0 M0 10 (24.4) NA NA
TX N1-N2 MX 11 (26.8) NA NA
TX NX M1 6 (14.6) NA NA
Missing 2 NA NA
NA¼not applicable.
aSome subjects had several invasive cancers and/or high-risk adenomas.
bRectum¼rectum+recto-sigmoidal junction.
cDistal colon¼left colon.
dProximal
colon¼right or transverse colon.
eTumour Node Metastasis (TNM) classification of malignant tumours.
Table 3 Comparison of tests sensitivity for advanced neoplasia according to location on the colon
Location
a and type of the most
Results of FOBT
b
RSN
c
severe lesion detected G
+I
+ (n¼141) G
+I
  (n¼249) G
 I
+ (n¼887) 2.63 (2.37–2.92)
Invasive cancer 25 2 16 1.48 (1.16–1.89)
Rectum 11 0 12 2.09 (1.36–3.20)
Distal colon 9 2 3 1.09 (0.74–1.60)
Proximal colon 6 0 1 1.17 (0.86–1.58)
High-risk adenoma 58 21 204 3.32 (2.70–4.07)
Rectum 11 4 40 3.40 (2.12–5.44)
Distal colon 44 11 122 3.02 (2.38–3.82)
Proximal colon 3 6 42 5.00 (2.55–9.82)
Small adenoma 17 40 194 3.70 (2.82–4.87)
Rectum 2 10 44 3.83 (2.08–7.08)
Distal colon 8 18 99 4.12 (2.75–6.15)
Proximal colon 8 13 75 3.95 (2.54–6.14)
aSome subjects had several invasive cancers and/or high-risk adenomas and several locations.
bFOBT¼faecal occult blood test; G
+/G
 ¼positive/negative guaiac FOBT;
I
+/I
 ¼positive/negative immunochemical FOBT.
cRSN¼ratio of sentivities; RSN41¼sensitivity of immunochemical FOBT is greater than that of guaiac FOBT.
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samount of bleeding of invasive cancers (mean¼86.6ng Hb per ml)
was higher than that of high-risk adenomas (mean¼71.9ng Hb
per ml) that was in turn higher than those of small adenomas
(mean¼52.7ng Hb per ml) or normal colon (mean¼54.3ng Hb
per ml). Bleeding amounts for cancer of the rectum were lower
than those for distal or proximal colon cancer, although non-
significant. Bleeding amounts for rectal cancers were only slightly
higher than that of high-risk adenomas located in the rectum and
distal colon. Bleeding amounts for high-risk adenomas of the
proximal colon were similar to those for small adenoma or normal
colon. In summary, severe lesions with the lowest amount of
bleeding (high-risk adenomas and rectal cancers) correspond to
those for which I-FOBT provides the most important gain in
sensitivity.
Haemoglobin detection level using G-FOBT Figure 2 illustrates
the variation in the G-FOBT positivity rate according to the
amount of bleeding measured by the automatic I-FOBT reader. To
the left of the figure (bleeding amount o40ng Hb per ml), the rate
of positive G-FOBTs remained around 2%, suggesting that G-FOBT
is not capable of detecting bleeding less than 40ng Hb per ml. To
the right of the figure (bleeding amount X40ng Hb per ml), no
gap in the positivity rate was observed, but rather an exponential
increase in G-FOBT positivity with increased Hb content detected
by the I-FOBT.
DISCUSSION
The extent of gain in sensitivity in screening for colorectal cancer
when using I-FOBT instead of G-FOBT depends on the type and
the location of lesions. It was higher for high-risk adenomas than
for cancers. Among cancers, the gain in sensitivity was essentially
confined to rectal cancers and concerned good prognosis cancers.
This gain in sensitivity was related to the small amount of bleeding
observed in such lesions.
Our study has several drawbacks. First of all, because subjects for
whom both tests were negative underwent no further evaluation by
colonoscopy, we were unable to provide an estimation of sensitivity
and specificity for each test. However, the use of RSN allowed us to
quantify the potential gain obtained through the substitution of
G-FOBT by I-FOBT for each lesion type and location. Moreover,
despite our large sample size, the number of discordant pairs was
low. Therefore, the size of confidence intervals was probably
underestimated (Cheng et al, 2000), and the effect of the location of
invasive cancers on RSN may be lesser than it appears in Table 3.
However, physiological rationale for these differences reinforces our
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Figure 1 Distribution of the maximal haemoglobin amount measured in positive I-FOBT (immunochemical faecal occult blood test) subjects according to
the most severe lesion and its location (subjects with only one lesion detected). HR adenoma, high-risk adenoma (adenoma X10mm or high-grade
dysplasia). Location: 1. rectumþrecto-sigmoidal junction; 2. distal colon; 3. proximal colon.
Table 4 Extension status of colorectal cancer
Rectum
G
+I
+a G
 I
+a Total Distal colon Proximal colon
T1-T2 N0 M0 3 5 8 6 0
T3-T4 N0 M0 4 2 6 3 1
TX N1 MX 2 3 5 4 3
TX NX M1 2 1 3 1 2
aNo cancer was detected in subject with a negative I-FOBT.
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Figure 2 Frequency of positive G-FOBT (guaiac faecal occult blood test)
according to result of the I-FOBT (immunochemical faecal occult blood
test; two samples).
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sconclusions. Furthermore, the measurement of bleeding amounts
was provided by the I-FOBT itself. It therefore depended on the
technical characteristics of this I-FOBT and could by biased. Only
one I-FOBT was used, and any extrapolation of our results to other
I-FOBTs should be performed with caution. Finally, a proportion of
the subjects included in our study did not undergo colonoscopy.
This is unlikely to have differentially biased the results because the
proportion was similar whatever the test results, and colonoscopy
was performed blinded to both.
Our study also has strengths. First, the study included
asymptomatic average-risk subjects. This is of particular impor-
tance because the differential amount of bleeding between
symptomatic (rectal haemorrhage) and asymptomatic cancers is
higher for rectal than for colonic cancers (Macrae and St John,
1987). Moreover, the comparison (both globally and according to
location) of sensitivity for the detection of invasive cancers and
high-risk adenomas benefited from the paired comparison of the
tests used in this study. Indeed, the sensitivity for the detection of
invasive cancers for each test has been studied essentially using
(with the exception of the Morikawa study) data from registries
(detection or incidence methods (Day, 1985)) (Launoy et al, 1997;
Morikawa et al, 2005; Castiglione et al, 2007). However, these
methods cannot be used to detect high-risk adenomas because of
their small probability of becoming symptomatic within 2 years,
unless they evolve towards invasive cancer. Therefore, appropriate
data are lacking to evaluate sensitivity for the detection of high-
risk adenomas.
We observed a higher gain in sensitivity using I-FOBT rather
than G-FOBT, for the detection of rectal rather than colonic
cancers. Our results are consistent with previous studies, suggest-
ing that the sensitivity of Haemoccult G-FOBT is stable whatever
the location (Launoy et al, 1997) and that the sensitivity of
Magstream I-FOBT is higher for rectalþdistal colonic tumours
than for proximal colonic tumours (Morikawa et al, 2005). A non-
significant increase in the sensitivity of the OC-sensor I-FOBT was
also observed for the detection of invasive cancers of the rectum
versus the colon (Castiglione et al, 2007).
Several considerations require to be developed to explain the
difference in sensitivity. They concern, first, the amount of
bleeding and second, test processing.
In accordance with our results, several authors have observed
that the sensitivity of the G-FOBT decreases as the amount of
bleeding of the lesion increases (Morris et al, 1976; Stroehlein et al,
1976; Herzog et al, 1982; Ahlquist et al, 1985; Macrae and St John,
1987). As in other studies, in our population, the measured
intensity of bleeding of invasive cancers was higher than that of
high-risk adenomas (Levi et al, 2007; Ciatto et al, 2007). Moreover,
we observed lower bleeding intensity in rectal cancers than in
cancers in others locations, which is also in line with observations
of Ciatto et al (2007) who found smaller although non-significant
bleeding amounts for cancers of the rectumþdistal colon rather
than proximal colon.
Difference in sensitivity according to location can also be
explained by test process considerations. The G-FOBT relies on the
detection of peroxidase-like activity of haem in Hb; thus, the
test detects both Hb and haem, which results either from the
deterioration of Hb or from feeding. Both haem and Hb are
deteriorated during intestinal transit and deteriorated globin
and haem-derived porphyrins are not detected by Haemoccult
(Goldschmiedt et al, 1988; Young et al, 1990). Herzog et al (1982)
observed that the positivity of the G-FOBT was determined by
the daily faecal blood loss and the anatomic location of colonic
bleeding sites. They found that the G-FOBT was more frequently
positive for distal rather than proximal colonic polyps of similar
Hb content.
The Magstream I-FOBT relies on an antibody directed against
the globin moiety of human Hb. Deteriorated Hb is not detected.
Immunochemical faecal occult blood test may underestimate the
intensity of bleeding in proximal polypoid lesions and, therefore,
be less sensitive to such lesions. This could explain why Morikawa
et al (2005) found that the sensitivity of the one-time Magstream
for the detection of adenomas measuring over 10mm was smaller
for proximal than for distal lesions (11 vs 25%), whereas Herzog
et al (1982) found no difference in bleeding intensity according to
the location of the lesion. Consequently, the constant RSN we
observed for the detection of high-risk adenomas throughout the
low digestive tract, which could correspond to a similar variation
in sensitivity of the I-FOBT and G-FOBT, is in accordance with
these findings.
Our previous studies have demonstrated that I-FOBT is
preferable to G-FOBT from a public health point of view because
the availability of quantitative Hb measurement offers the
possibility to choose a positivity rate offering both high sensitivity
and high specificity (Launoy et al, 2005; Guittet et al, 2007). This
study suggests that I-FOBT is also preferable to G-FOBT from a
clinical point of view, because it is capable of detecting good
prognosis cancers of the rectum and high-risk adenomas that are
missed by G-FOBT. This is of particular importance because, in
colorectal cancers, the proportion of those located in the rectum
varies from 30 to 45% in different cancer registries (Parkin et al,
2005). The higher gain in sensitivity for good prognosis cancers
should enhance the expected gain in survival through screening by
using the I-FOBT. Further studies are needed to evaluate the
relevance of adapting the confirmatory test to the level of positivity
offered by the I-FOBT, using a rectosigmoidoscopy for subjects
with a weak positive I-FOBT (small amounts of bleeding) and a
colonoscopy for subjects with a strong positive I-FOBT.
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